- Home
- SLND vs VTYX Comparison
SLND vs VTYX Comparison
Compare SLND & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- VTYX
- Stock Information
- Founded
- SLND 1900
- VTYX 2018
- Country
- SLND United States
- VTYX United States
- Employees
- SLND N/A
- VTYX N/A
- Industry
- SLND Military/Government/Technical
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- SLND Industrials
- VTYX Health Care
- Exchange
- SLND Nasdaq
- VTYX Nasdaq
- Market Cap
- SLND 175.8M
- VTYX 154.9M
- IPO Year
- SLND N/A
- VTYX 2021
- Fundamental
- Price
- SLND $4.49
- VTYX $2.08
- Analyst Decision
- SLND Strong Buy
- VTYX Buy
- Analyst Count
- SLND 1
- VTYX 4
- Target Price
- SLND $5.00
- VTYX $11.33
- AVG Volume (30 Days)
- SLND 72.5K
- VTYX 2.2M
- Earning Date
- SLND 08-11-2025
- VTYX 08-07-2025
- Dividend Yield
- SLND N/A
- VTYX N/A
- EPS Growth
- SLND N/A
- VTYX N/A
- EPS
- SLND N/A
- VTYX N/A
- Revenue
- SLND $931,568,000.00
- VTYX N/A
- Revenue This Year
- SLND $3.76
- VTYX N/A
- Revenue Next Year
- SLND $1.08
- VTYX N/A
- P/E Ratio
- SLND N/A
- VTYX N/A
- Revenue Growth
- SLND N/A
- VTYX N/A
- 52 Week Low
- SLND $1.85
- VTYX $0.78
- 52 Week High
- SLND $4.67
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- SLND 71.29
- VTYX 47.92
- Support Level
- SLND $3.66
- VTYX $1.95
- Resistance Level
- SLND $4.62
- VTYX $2.51
- Average True Range (ATR)
- SLND 0.26
- VTYX 0.19
- MACD
- SLND 0.05
- VTYX -0.08
- Stochastic Oscillator
- SLND 87.04
- VTYX 19.12
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.